Reports

Sale

Oncology Based In-Vivo CRO Market

Global Oncology Based In-Vivo CRO Market Size, Share, Price, Growth, Forecast: By Indication: Blood Cancer, Solid Tumors, Other Indications; By Model: Syngeneic, Xenograft, Patient Derived Xenograft (PDX); Regulatory Framework; Patent Analysis; Grants Analysis; Clinical Trials Analysis; Regional Analysis; Supplier Landscape; 2024-2032

Global Oncology Based In-Vivo CRO Market Outlook

The global oncology based in-vivo CRO market size was valued at USD 1.19 billion in 2023, driven by the development of non-viral delivery systems across the globe. The market is anticipated to grow at a CAGR of 7.9% during the forecast period of 2024-2032 to achieve a value of USD 2.35 billion by 2032.

 

Oncology Based In-Vivo CRO: Introduction

Oncology based in-vivo CRO provides specialized services in the field of oncology research. A diverse range of services is provided by this organization in order to support the development of new oncology therapies and treatments. The main services provided by Oncology based In-Vivo CRO are study design, selection and validation of animal model, data collection and analysis, and regulatory compliance, along with dosing and drug administration, and tumor imaging and measurement.

 

The specialized CROs provide knowledge and experience in the conduct of investigations and tests employing in vivo models, such as animal models, to assess the efficacy and safety of new oncology treatments. Through the use of in vivo tumor models, xenograft and syngeneic models, pharmacokinetic investigations, toxicological analyses, and efficacy studies, in-vivo CROs offer thorough evaluation of potential oncology medications. They aid in finding indicators of therapy response or resistance, helping to test novel cancer therapies, and analyzing how treatments affect tumor growth and metastasis.

 

Global Oncology based In-Vivo CRO Market Analysis

Expert services are provided by these organizations due to the access they have to advanced technologies and equipment that are required and necessary to conduct in-vivo studies. The expansion of personalized medicine owing to the market growth. By offering preclinical services that promote the development of targeted medicines and ease the discovery and validation of biomarkers, in-vivo CROs are significantly contributing to the advancement of personalized medicine. Additionally, the field of immuno-oncology harnesses the body's immune system to fight cancer has also been witnessing significant growth, leading to further oncology based in-vivo CRO market expansion.

 

In-Vivo CROs actively conducting preclinical studies to evaluate the efficacy and safety of immunotherapies and combination therapies to support the immuno-oncology research, propelling the oncology based in-vivo CRO market growth. The increased integration of artificial intelligence and machine learning technologies to improve the quality of data analysis, image processing, and predictive modeling are directly contributing to the market growth. In-Vivo CROs are the technologies that enables better interpretation of complex preclinical data and facilitate the identification of novel biomarkers, improving decision-making processes and accelerating drug discovery efforts.

 

Global Oncology based In-Vivo CRO Market Segmentations

Market Breakup by Indication

  • Blood Cancer
  • Solid Tumors 
  • Other Indications

 

Market Breakup by Model

  • Syngeneic 
  • Xenograft 
  • Patient Derived Xenograft (PDX)

 

Market Breakup by Region

  • North America 
  • Europe 
  • Asia Pacific 
  • Latin America 
  • Middle East and Africa

 

Global Oncology based In-Vivo CRO Market Overview

The market for oncology based in-vivo CRO has been witnessing evident growth in the past and is expected to see the growth in coming years as well owing to the increasing prevalence of cancer worldwide. The demand for newly developed therapies that are effective and innovative has increased and has created an emphasis on research and development for these therapies in the oncology filed. The demand for cost-effective and time-efficient drug development procedures has also been a driver for market growth.

 

In-vivo CROs provide specialised knowledge in creating and using animal models that closely resemble the characteristics of human cancers, enabling the assessment of targeted treatments and individualised treatment plans. This is further aiding the oncology based in-vivo CRO market development.

 

To ensure that only the highest-quality products are let onto the market, health authorities have established strict regulatory restrictions on pharmaceutical businesses. In-Vivo CROs help these companies adhere to these regulations. In-Vivo CROs assist in ensuring that potential oncology treatments meet the requisite safety and efficacy requirements for further development and clinical trials by conducting preclinical research in accordance with Good Laboratory Practise (GLP) standards which directly contributes to the market growth.

 

Oncology based In-Vivo CRO Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Crown Bioscience Inc.
  • Charles River Laboratories Inc.  
  • ICON PLC  
  • Taconic Biosciences Inc.  
  • Covance Inc.  
  • Eurofins Scientific  
  • EVOTEC  
  • The Jackson Laboratory 
  • Wuxi AppTec.  
  • MI Bioresearch Inc.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Indication
  • Model
  • Region
Breakup by Indication
  • Blood Cancer
  • Solid Tumors 
  • Other Indications
Breakup by Model
  • Syngeneic 
  • Xenograft 
  • Patient Derived Xenograft (PDX)
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Crown Bioscience Inc.
  • Charles River Laboratories Inc.  
  • ICON PLC  
  • Taconic Biosciences Inc.  
  • Covance Inc.  
  • Eurofins Scientific  
  • EVOTEC  
  • The Jackson Laboratory 
  • Wuxi AppTec.  
  • MI Bioresearch Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Global Oncology Based In-Vivo Cro Market Overview
 
    3.1    Global Oncology Based In-Vivo Cro Market Historical Value (2017-2023) 
    3.2    Global Oncology Based In-Vivo Cro Market Forecast Value (2024-2032)
4    Global Oncology Based In-Vivo Cro Market Landscape
    4.1    Image Guided Surgery: Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Image Guided Surgery: Product Landscape
        4.2.1    Analysis by Type
        4.2.2    Analysis by Indication
5    Global Oncology Based In-Vivo Cro Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6    Global Oncology Based In-Vivo Cro Market Segmentation
    6.1    Global Oncology Based In-Vivo Cro Market by Indication
        6.1.1    Market Overview
        6.1.2    Blood Cancer
        6.1.3    Solid Tumors
        6.1.4    Other Indications 
    6.2    Global Oncology Based In-Vivo Cro Market by Model
        6.2.1    Market Overview
        6.2.2    Syngeneic
        6.2.3    Xenograft
        6.2.4    Patient Derived Xenograft (PDX) 
    6.3    Global Oncology Based In-Vivo Cro Market by Region
        6.3.1    Market Overview
        6.3.2    North America
        6.3.3    Europe 
        6.3.4    Asia Pacific
        6.3.5    Latin America
        6.3.6    Middle East and Africa
7    North America Oncology Based In-Vivo Cro Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Oncology Based In-Vivo Cro Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Oncology Based In-Vivo Cro Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Oncology Based In-Vivo Cro Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Oncology Based In-Vivo Cro Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Regulatory Framework
    12.1    Regulatory Overview
        12.1.1    US FDA
        12.1.2    EU EMA
        12.1.3    INDIA CDSCO
        12.1.4    JAPAN PMDA
        12.1.5    Others
13    Patent Analysis
    13.1    Analysis by Type of Patent
    13.2    Analysis by Publication year
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Patent Age
    13.5    Analysis by CPC Analysis
    13.6    Analysis by Patent Valuation 
    13.7    Analysis by Key Players
14    Grants Analysis
    14.1    Analysis by year
    14.2    Analysis by Amount Awarded
    14.3    Analysis by Issuing Authority
    14.4    Analysis by Grant Application
    14.5    Analysis by Funding Institute
    14.6    Analysis by NIH Departments
    14.7    Analysis by Recipient Organization 
15    Clinical Trials Analysis
    15.1     Analysis by Trial Registration Year
    15.2    Analysis by Trial Status
    15.3    Analysis by Trial Phase
    15.4    Analysis by Therapeutic Area
    15.5    Analysis by Geography
16    Funding and Investment Analysis
    16.1    Analysis by Funding Instances
    16.2    Analysis by Type of Funding
    16.3    Analysis by Funding Amount
    16.4    Analysis by Leading Players
    16.5    Analysis by Leading Investors
    16.6    Analysis by Geography
17    Partnership and Collaborations Analysis
    17.1    Analysis by Partnership Instances
    17.2    Analysis by Type of Partnership
    17.3    Analysis by Leading Players
    17.4    Analysis by Geography
18    Supplier Landscape
    18.1    Crown Bioscience Inc. 
        18.1.1    Financial Analysis
        18.1.2    Product Portfolio
        18.1.3    Demographic Reach and Achievements
        18.1.4    Mergers and Acquisitions
        18.1.5    Certifications 
    18.2    Charles River Laboratories Inc. 
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisitions
        18.2.5    Certifications
    18.3    ICON PLC 
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisitions
        18.3.5    Certifications
    18.4    Taconic Biosciences Inc. 
        18.4.1    Financial Analysis
        18.4.2    Product Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisitions
        18.4.5    Certifications
    18.5    Covance Inc. 
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisitions
        18.5.5    Certifications
    18.6    Eurofins Scientific 
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisitions
        18.6.5    Certifications
    18.7    EVOTEC 
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisitions
        18.7.5    Certifications
    18.8    The Jackson Laboratory
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisitions
        18.8.5    Certifications
    18.9    Wuxi AppTec. 
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisitions
        18.9.5    Certifications
    18.10    MI Bioresearch Inc. 
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisitions
        18.10.5    Certifications
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket
    

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 1.19 billion in 2023, driven by the increasing demand for newly developed therapies.

The market is anticipated to grow at a CAGR of 7.9% during the forecast period of 2024-2032 to reach a market value of USD 2.35 million by 2032.

The increasing demand for cost-effective and time-efficient drug development procedures are among the key drivers aiding the market growth.

The technological advancement in the imaging process and demand for personalized medicine market are the key trends driving the market growth.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.

The models in the market include syngeneic xenograft and patient derived xenograft (PDX).

The different indications of oncology based In-Vivo CRO include blood cancer, solid tumors, other indications.

Key players involved in the market include Crown Bioscience Inc., Charles River Laboratories Inc., ICON PLC, Taconic Biosciences Inc., Covance Inc., Eurofins Scientific, EVOTEC, The Wuxi AppTec., MI Bioresearch Inc., and Jackson Laboratory.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER